Size: | Price | Quantity | |
---|---|---|---|
10 Mg | $40.00 | ||
50 Mg | $125.00 |
Camostat mesilate (59721-29-8) is a serine protease inhibitor inhibiting plasmin, kallikrein, thrombin as well as trypsin, which attenuates pancreatic fibrosis.1 Reduces weight gain and improves metabolism in obese rodent models.2 In clinical use (in Japan) for pancreatitis.3 Inhibits influenza virus replication in human tracheal epithelial cells.4 Reduces infection of Calu-3 lung cells by SARS-CoV-2 (responsible for COVID-19) via inhibition of the serine protease TMPRSS2 required for viral spike protein priming.5
References/Citations:
1) Gibo et al. (2005), Camostat mesylate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity; Lab Invest., 85 75
2) Albarazanji et al. (2019), Intestinal serine protease inhibition increases FGF21 and improves metabolism in obese mice.; Am. J. Physiol. Gastrointest. Liver Physiol., 316 G653
3) Ueda et al. (2015), The serine protease inhibitor camostat mesylate attenuates the progression of chronic kidney disease through its antioxidant effects; Nephron, 129 223
4) Yamaya et al. (2015), The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells; Pulm. Pharmacol. Ther., 33 66
5) Hoffmann et al. (2020), SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor; Cell, 181 271
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Camostat mesilate (59721-29-8) is a serine protease inhibitor inhibiting plasmin, kallikrein, thrombin as well as trypsin, which attenuates pancreatic fibrosis.1 Reduces weight gain and improves metabolism in obese rodent models.2 In clinical use (in Japan) for pancreatitis.3 Inhibits influenza virus replication in human tracheal epithelial cells.4 Reduces infection of Calu-3 lung cells by SARS-CoV-2 (responsible for COVID-19) via inhibition of the serine protease TMPRSS2 required for viral spike protein priming.5
References/Citations:
1) Gibo et al. (2005), Camostat mesylate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity; Lab Invest., 85 75
2) Albarazanji et al. (2019), Intestinal serine protease inhibition increases FGF21 and improves metabolism in obese mice.; Am. J. Physiol. Gastrointest. Liver Physiol., 316 G653
3) Ueda et al. (2015), The serine protease inhibitor camostat mesylate attenuates the progression of chronic kidney disease through its antioxidant effects; Nephron, 129 223
4) Yamaya et al. (2015), The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells; Pulm. Pharmacol. Ther., 33 66
5) Hoffmann et al. (2020), SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor; Cell, 181 271
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.